Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Terminal Respiratory Unit Type Lung Adenocarcinoma is Associated With Distinctive EGFR Immunoreactivity and EGFR Mutations

Terminal Respiratory Unit Type Lung Adenocarcinoma is Associated With Distinctive EGFR... RESEARCH ARTICLE Terminal Respiratory Unit Type Lung Adenocarcinoma is Associated With Distinctive EGFR Immunoreactivity and EGFR Mutations Michael R. Peterson, MD, PhD,* Zhe Piao, MD, PhD,* Lyudmila A. Bazhenova, MD,w Noel Weidner, MD,* and Eunhee S. Yi, MD* important roles in the proliferation and metastasis of Abstract: Approximately 10% to 20% of nonsmall cell lung tumor cells. EGFR is a favored target for orally cancer patients respond to epidermal growth factor receptor administered small-molecule and antibody-based therapy. (EGFR) tyrosine kinase inhibitors, such as gefitinib. Responders Nonsmall cell lung cancer frequently expresses EGFR are mostly nonsmokers and women with tumors displaying and two EGFR inhibitors [gefitinib (Iressa, Astra- bronchioloalveolar features. Mutations of the tyrosine kinase Zeneca) and erlotinib (Tarceva, OSI Pharmaceuticals)] domain of the EGFR gene have been associated with a clinical have been approved by the FDA as third-line therapy for response to gefitinib. A recent study reported that the terminal nonsmall cell lung cancer since May 2003. respiratory unit (TRU)-type adenocarcinoma shares the clinical Clinical trials using gefitinib have shown a response profile and EGFR mutations of gefitinib responders. EGFR rate of approximately 10% to 20%. Phase 2 studies have immunoreactivity in this context has not been reported http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Terminal Respiratory Unit Type Lung Adenocarcinoma is Associated With Distinctive EGFR Immunoreactivity and EGFR Mutations

Loading next page...
 
/lp/wolters-kluwer-health/terminal-respiratory-unit-type-lung-adenocarcinoma-is-associated-with-0FWy9iXb7h

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1541-2016
DOI
10.1097/PAI.0b013e31802d1590
pmid
17721266
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE Terminal Respiratory Unit Type Lung Adenocarcinoma is Associated With Distinctive EGFR Immunoreactivity and EGFR Mutations Michael R. Peterson, MD, PhD,* Zhe Piao, MD, PhD,* Lyudmila A. Bazhenova, MD,w Noel Weidner, MD,* and Eunhee S. Yi, MD* important roles in the proliferation and metastasis of Abstract: Approximately 10% to 20% of nonsmall cell lung tumor cells. EGFR is a favored target for orally cancer patients respond to epidermal growth factor receptor administered small-molecule and antibody-based therapy. (EGFR) tyrosine kinase inhibitors, such as gefitinib. Responders Nonsmall cell lung cancer frequently expresses EGFR are mostly nonsmokers and women with tumors displaying and two EGFR inhibitors [gefitinib (Iressa, Astra- bronchioloalveolar features. Mutations of the tyrosine kinase Zeneca) and erlotinib (Tarceva, OSI Pharmaceuticals)] domain of the EGFR gene have been associated with a clinical have been approved by the FDA as third-line therapy for response to gefitinib. A recent study reported that the terminal nonsmall cell lung cancer since May 2003. respiratory unit (TRU)-type adenocarcinoma shares the clinical Clinical trials using gefitinib have shown a response profile and EGFR mutations of gefitinib responders. EGFR rate of approximately 10% to 20%. Phase 2 studies have immunoreactivity in this context has not been reported

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Sep 1, 2007

There are no references for this article.